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Abstract 
The neurodegenerative process in Parkinson’s disease (PD) results in a relentless progression 
of motor and non-motor symptoms. Affected individuals are frequently hospitalised for 
complications of the disease including falls, fractures, infections, and neuropsychiatric 
symptoms. When admitted to hospital, inpatient care is often suboptimal as it focusses on the 
primary cause of admission, and is associated with poor patient outcomes and significant 
healthcare costs. Aim: To review existing literature for evidence-based interventions aimed at 
reducing hospital admissions in PD Methods: Electronic literature search in EMBASE, 
MEDLINE and CINAHL databases for studies evaluating interventions to reduce hospital 
admissions in PD. We included publications with full abstracts, published in the English 
language and addressing interventions to reduce hospital admissions in PD. Results: To date 
there are no randomised controlled trials addressing the topic. We identified nine relevant 
retrospective studies. Results from these studies suggest an association between frequent 
neurologist consultations, open access clinics, and medication compliance with a reduction in 
PD hospital admissions and emergency room visits. Conclusion: This systematic review 
highlights the lack of robust evidence for measures aimed at reducing hospital admissions in 
people with PD. Future prospective studies are required to evaluate the effectiveness of 
proposed interventions. 
Word count: 2668 
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Introduction 
Motor and non-motor symptoms in Parkinson’s disease (PD) steadily progress with 
advancing disease leading to complications such as falls, fractures, and infections; which are 
compounded by cognitive decline and Parkinson’s dementia. As a consequence, individuals 
with the disease are admitted to hospital more often than people without PD.[1, 2] In 
addition, medication-related complications add to the disease burden and increase the 
likelihood of hospital encounters.[3] Once PD patients are admitted to hospital, they have 
prolonged inpatient stays,[4] poor motor outcomes, infections, prescription errors, increased 
postoperative mortality,[5-8] and are more likely to have repeat hospital admissions.[9] A 
study in the United States reported a significant economic burden from PD hospitalisation: 
approximately 20% of estimated annual cost for PD ($4.6 billion US dollars) was due to 
inpatient costs.[4] Similarly in the UK, there is a substantial cost from non-elective PD 
admissions (annual expenditure £194 million).[10] Given the aging population, these costs 
are likely to rise. 
Given the scale of PD hospitalisation, the associated morbidity, mortality, and costs, there is a 
need for interventions to reduce unplanned PD hospital admission. Such interventions should 
be cost-effective and focussed on reducing known risk factors for hospitalisation. The 
purpose of this article was to systematically review available literature for effective 
interventions aimed at preventing unplanned hospital admissions in individuals with PD. 
Methods  
 A search for publications from EMBASE, MEDLINE and CINAHL databases up to 
September 2014 was performed. Eligibility criteria included randomised controlled trials 
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(RCTs) evaluating effectiveness of intervention versus no intervention in reducing hospital 
admissions and/or emergency department visits in patients with PD. Index terms and free text 
terms for ‘Parkinson’s disease’, Parkinson ⃰, ‘hospitalisation’, and hospital⃰ were used but this 
yielded no relevant randomised controlled trials. The search criteria were therefore broadened 
to include other study types. We included all studies where a specific measure was employed 
and led to a reduction in number of hospital admissions or emergency department visits in 
PD. Interventions included those that have been used in other chronic diseases to reduce 
unplanned hospital admissions such as patient educational programmes, urgent access clinics, 
specialist’s clinics and specialist nurses. Outcome measures included a reduction in either 
hospital admission, non-elective, unplanned admissions, or emergency room visits. Study 
participants were individuals with PD of all disease stages and duration. No age restrictions 
were applied. Abstracts and title headings were screened and only publications with full 
abstracts, published in the English language and addressing interventions to reduce hospital 
admissions in PD were included. 
Results.   
7,610 abstracts obtained from the three data sources were screened. Duplicates and 
publications addressing hospitalisation in conditions other than PD were excluded. 115 
articles and abstracts were assessed for eligibility. From these, 105 excluded articles 
discussed issues pertaining to PD hospitalisation such as frequency and reasons for 
admissions, inpatient care and medication errors, but did not assess the effect of specific 
interventions on reducing hospital admissions in PD (figure 1). We found one randomised 
controlled trial (RCT) which assessed the effectiveness of two dysphagia management 
techniques in reducing the aspiration pneumonia and also measured hospitalisations as an 
adverse event.[11] Nine retrospective studies reported a change in healthcare utilisation 
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including the number of emergency visits and or hospitalisation after an intervention and 
these were included (Table 1). [12-20] 
One RCT compared the incidence of pneumonia among 515 patients with dementia and PD 
who were randomised to either chin-down posture technique or two types of thickened fluids 
(nectar- and honey-thick consistencies) over a 3 month follow up period.[11] There was no 
difference in the incidence of pneumonia (primary outcome measure) between the two 
interventions. When the two types of thickened fluids were compared the cumulative 
incidence for pneumonia was less in the nectar-thick fluid compared to honey-thick fluid 
(0.08 and 0.15 respectively; HR 0.50 95% CI 0.23, 1.09).[11] The overall incidence of 
pneumonia reported in this study was low, however authors could not attribute the low 
incidence to the interventions used in this study because no placebo group was included.[11]  
Hospitalisations were reported as an adverse event and 20% of participants had at least one 
hospital admission in each of the two intervention arms. The number of withdrawals due to 
adverse events, including hospitalisations, was higher in the thickened fluid group (4%) 
compared to chin down posture group (2%); 2% difference, CI -0.4%, -5%). 
A retrospective cohort study among 24,929 Medicare recipients in the United States (US) 
evaluated the effect of frequent neurologist care on PD hospitalisation and reported a 
reduction in hospital admissions for traumatic injury (HR 0.56, 95% CI 0.40-0.78), psychosis 
(HR 0.71, 95% CI 0.59-0.86) and urinary tract infection (HR 0.74 95% CI 0.63-0.87) in 
patients who had frequent neurologist care compared to those who were not treated by a 
neurologist.[12] Another US survey assessed the impact of neurologist care on healthcare 
costs and utilisation among 3,883 individuals with chronic neurological conditions including 
parkinsonism and showed that respondents who had consulted a neurologist had a reduction 
in disease-related home care, emergency, and inpatient care events compared to those with no 
neurologist involvement (OR 0.64, P=0.001).[13] In another retrospective study, PD patients 
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with poor motor symptom control, medication-related complications, or neuropsychiatric 
symptoms were allowed to access an urgent neurology clinic without prior appointment. This 
resulted in a 50% reduction in PD admissions over a 2 year period.[14] In addition there was 
a reduction in hospital length of stay from 11 to 4.5 days.[14]  
Two retrospective studies reported fewer hospital admissions in PD patients treated with 
rasagiline when compared to dopamine agonists[15] or selegiline.[16] Comparisons of the 
number, duration, and cost of hospital admissions for 7,230 PD patients who were initially 
treated with either a dopamine agonist or rasagiline were compared using data from the 
Medicare Supplemental Database. The authors reported fewer hospital admissions (OR 0.76, 
95% CI 0.66-0.86), shorter duration of stay (-0.38 day p< 0.0001), and reduced costs in 
rasagiline-treated patients compared to the DA group: $12,327 versus $16,525  
respectively.[15] In a retrospective study involving 3,864 individuals with PD, Grubb et al 
showed that, rasagiline use was associated with lower emergency room visits (odds ratio: 
0.79; 95% CI, 0.68 to 0.92) and all  cause hospital admissions (odds ratio: 0.82; 95% CI, 0.68 
to 0.99) compared to the selegiline-treated group.[16] However, no difference was found in 
the odds of PD-related hospital admissions and fractures.[16]  
Four retrospective studies assessed the frequency of medication adherence in PD and also 
measured hospitalisation as an outcome. In a retrospective historical cohort study which 
included 1,215 from a US health claim database, Delea et al showed that patients with 
satisfactory levodopa/carbidopa/entacapone therapy compliance (proportion of days where a 
patient had medication supply  ≥80%), had 49% fewer emergency room visits (p=0.010) and 
39% less PD-related hospitalisations compared to the non-adherent group (p=0.001).[17] The 
number of all hospitalisations and overall PD-related costs were also lower in the group of 
patients with satisfactory treatment adherence.[17] In another study of 104 PD patients, 
suboptimal adherence to PD medication was associated with worsening motor symptoms.[19] 
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PD related hospitalisations and emergency room visits were used as an indicator of 
worsening motor symptoms, in addition to an increase PD medication dosage. Medication 
possession ratio (MPR), a measure of medication adherence was defined as the proportion of 
days covered by a PD prescription: the numerator was the number of days covered by a PD 
prescription and the denominator was the number of days between prescription 
disbursements.[19]. During the first year of follow up, the mean possession ratio, PD related 
emergency room visits, and hospitalisation were 0.52 ± 0.35, 0.07 ± 0.29, and 0.91± 2.19 
respectively. In the 5th year the MPR was lower 0.42 ± 0.37 with higher emergency room 
visits and hospitalisation: 0.18± 0.70 and 1.40± 3.74. [19] In a retrospective cross-sectional 
study, Wei et al used Medicare administrative data for 7,583 patients with PD and found that 
those with a medication possession ratio of more than 90% had lower emergency room visits 
and hospitalisation rate than poor adherers (less 80% MPR).[18] Another US study evaluated 
the prevalence and cost of poor adherence to PD medication using retrospective 
administrative and claims data. The study included 3,119 participants who had a PD 
International classification of diseases (ICD) code recorded and were on PD medications 
during the study period. The mean number of hospitalisations over 12 months was 
significantly higher amongst individuals who were non-compliant with PD medication in 
comparison to the compliant group (2.3 versus 1.8; p<0.005).[20] However, there was no 
difference in the mean number of emergency room visits.[20] Mean health costs were 
significantly higher in the non-adherent group.[20] 
Discussion 
Hospitalisation in PD is a significant cost-driver[21] and patient outcome is often poor.[3-5] 
This review highlights the lack of evidence-based interventions for reducing PD patient 
hospitalisation.  
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Of the few studies we did find in this area, only one RCT of a specific intervention was 
found. This reported an low overall pneumonia incidence and no difference in the frequency 
of pneumonia when either chin-down posture or thickened fluids were used to manage 
dysphagia.[11] This study was limited by a short follow up period and the absence of a 
control group.[11] There was no difference in hospitalisation rates between the two 
interventions. Further, the cumulative pneumonia incidence was less when fluids with nectar 
compared to honey consistency were used.[11] This difference could have been a chance 
finding because the overall incidence of pneumonia in the study was low. Although 
speculative, the low pneumonia rates reported in the study suggests that chin-down posture 
and fluids of nectar/honey consistency may be useful interventions for pneumonia prevention.  
We identified nine retrospective studies where hospitalisation rates and emergency room 
visits in PD were measured. These studies suggested that frequent neurologist consultation, 
open access clinics, and compliance with PD medication may reduce hospital admissions and 
emergency room attendance by PD patients. The cost effectiveness and the actual number and 
frequency of neurological consultations required to reduce PD hospitalisation is uncertain. 
Frequent consultations may provide opportunities for medication adjustments, earlier 
detection and management of complications which, in turn, reduces the need for 
hospitalisation.[12] Open access clinics also provide similar opportunities for symptoms and 
complication management which potentially prevents hospital admissions.[14] The 
effectiveness of open access clinics was based on a report from a single centre with no 
comparison group. An association between PD medication adherence and reduction in 
emergency room visits and PD-related hospital admissions was reported in four retrospective 
studies.[17-20] Sub-optimal adherence to PD medication can have negative implications on 
motor outcomes and patient quality of life.[22] These findings imply that optimising PD 
symptom control through medication compliance possibly reduces hospital admissions for 
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poor motor control. Interventions such as regular neurologist care and open access clinics 
may be difficult to implement in countries where some individuals have no health insurance. 
In addition, some patients may not be able to afford their PD prescriptions which may impact 
on medication adherence, motor symptom control, and therefore hospitalisation. A surprising 
finding was the association between rasagiline treatment and fewer hospital admissions 
reported in two retrospective studies.[15, 16] Dopamine agonists have superior symptomatic 
effects compared to monoamine oxidase inhibitor treatment. However, dopamine agonist 
treatment is associated with more side effects.[23] This may account for the fewer 
hospitalisations in rasagiline group. The differences in emergency room visits between 
selegiline and rasagiline treated patients cannot be explained. These two studies were funded 
by the rasagiline manufacturer which may have led to bias. 
A major limitation of these studies is their retrospective design. Reliability of the reported 
results is dependent on the accuracy of the databases from which the data were extracted. It is 
also impossible to control for all confounding factors in such studies. Therefore, definitive 
conclusions regarding the effectiveness of the above interventions cannot be drawn based on 
this evidence. Nevertheless, these studies provide some insight into the interventions that 
require further evaluation. 
Falls, fractures, infections, cognitive, and motor decline have been identified as risk factors 
for unplanned hospital admissions in patients with PD.[9] Implementing preventative 
measures for these complications may reduce the need for hospital admission. Falls in PD can 
occur as a result of postural instability, poor motor symptom control, and drug-related side 
effects (e.g. postural hypotension). Optimising motor symptom control and managing 
medication side effects may prevent falls and hence hospital admissions. Furthermore 
physiotherapy is thought to improve PD motor symptoms, mobility, and balance,[24] which  
may also potentially reduce the risk of falls. A recent Cochrane review compared the 
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effectiveness of physiotherapy interventions and no intervention in PD on outcomes such as 
gait, falls, and clinician-rated measures of impairment and disability. Health resource usage 
including hospitalisation was not reported as an outcome measure. Although there was a 
reported trend towards improvement in falls, there was no significant difference in the 
number of falls between the physiotherapy and non-intervention arms in 6 studies from which 
data could be abstracted.[24] The authors reported that the absence of a positive effect from 
physiotherapy could have been a result of short follow up periods, reliance on falls diaries, 
and the small number of participants in the included studies.[24] In terms of fracture 
prevention, there is good evidence that osteoporosis prevention strategies such as Vitamin D 
supplementation and bisphosphonates improve bone mineral density and reduce fracture risk 
in PD.[25] Fracture prevention measures may reduce hospitalisation as shown in an Italian 
retrospective study which included 5,167 postmenopausal women who were discharged from 
hospital with primary or secondary diagnosis of hip fracture.[26] The study compared the 
effect of treatment or no treatment with fracture prevention medication on mortality, re-
fracture rates, and costs of health resource use (including hospitalisation). For those who 
were treated with bisphosphonates, the effect of compliance with treatment on these outcome 
measures was also assessed.[26] Only 34% of the included patients were exposed to fracture 
prevention treatments and 1,044 events (deaths and hospitalisation) were reported, and these 
were related to re-fractures.[26] A significantly reduced incidence of death (-55%, p<0.001 ) 
and re-fracture related hospitalisations (-40% p<0.001) was reported when fracture treatment 
was used.[26] In those who were treated with bisphosphonates, adherence of <40% was 
associated with higher total costs including re-hospitalisation, compared to those with better 
adherence.[26] It is uncertain if osteoporosis and fracture prevention measures translate into a 
reduction in hospitalisation rates in PD. Early speech and language therapy involvement in 
dysphagia management may potentially reduce the number of hospital admissions for 
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aspiration pneumonia. To date, no studies have systematically assessed whether pneumonia, 
falls, and fracture prevention strategies discussed above can reduce the number of hospital 
admissions in PD.  
PD nurse specialists, where available, may play a crucial role in identifying PD patients in the 
community who are at high risk of hospitalisation. By working in liaison with other PD 
specialists in primary and secondary care, social services, palliative care and rehabilitation 
services, early treatment can be instituted in the patients’ home. Community PD nurse care 
has been shown to be cost neutral when compared to primary care physicians, in a 
randomised controlled trial.[27] However, effectiveness of this approach in reducing PD 
hospitalisation rates has not been assessed.   
 Interventions such as specialist clinics (multidisciplinary or nurse-led),[28] medication 
management,[29] and patient self-management educational programmes,[30] have been 
shown to be effective in reducing unplanned admissions in other chronic conditions. The 
limited evidence that is available in PD does suggest that specialist clinics and medication 
management may reduce hospitalisation and therefore these interventions require further 
evaluation.  
This systematic review has highlighted a gap in evidence-base for interventions that are 
effective in reducing PD hospital admissions. Proposed measures are based mainly on 
retrospective studies and none have been systematically assessed in PD. Nevertheless, these 
interventions merit further evaluation in well-designed prospective trials. Considering the 
complexity of managing PD, it is likely that a multimodal approach which addresses motor 
and non-motor complications, as well as palliatives aspects in end-stage disease, may be 
more effective compared to a single intervention approach. In view of the health costs and 
morbidity associated with PD hospitalisation, it is imperative that PD experts and policy 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
makers make a joint effort to finding ways to reduce hospitalisation in PD as the search for 
disease modifying treatment continues. 
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Table 1: Proposed interventions for reducing Parkinson’s disease hospital admissions. 
Proposed intervention 
Author, year 
Study type Study Group Study intervention Outcome Effect of proposed intervention on hospitalisation 
and emergency room visits 
Dysphagia management       
Robbins et al 2008[20] 
 
Randomised 
Controlled 
Trial 
515 
(PD and 
dementia 
patients) 
Chin down posture 
versus honey/nectar thick 
fluid 
Pneumonia incidence, 
Hospitalisation measured as an 
adverse event 
No difference in serious adverse events (including 
hospitalisation) between the two intervention grroups 
Frequent Neurologist 
involvement 
     
Willis et al 2012[11] 
 
Retrospective 
cohort  
 
24929 
PD patients 
 
Neurologist versus no 
neurologist care 
 
PD-related and general medical 
related hospitalisation 
Neurologist care associated with ↓ hospitalisation for 
traumatic injury (HR 0.56, 95% CI 0.40-0.78), 
psychosis (HR 0.71, 95% CI 0.59-0.86) and urinary 
tract infection (HR 0.74 95% CI 0.63-0.87). 
Ney  et al 2013[12] Survey  
 
3883 
Parkinsonism, 
multiple 
sclerosis, 
epilepsy, 
dementia. 
Neurologist  ambulatory 
care 
Utilization and cost of non-
ambulatory care : inpatient, 
emergency, and home care 
 
↓ in condition related emergency, inpatient, and 
homecare care events (OR 0.64, P=0.001) and costs ( 
53% ,p<0.001) 
Open acess clinic      
Klein et al 2009[13] Retrospective  143 
PD patients 
Open access clinie Mean number of 
hospitalisations per year, mean 
length of stay 
50% ↓ in average number of PD admissions  over 2 
years : 36  to 18 
PD medication choice      
Grubb  et al 2012[14] 
 
Retrospective 
 
 
 
7230 
PD patients 
 
 
Rasagiline versus 
dopamine agonists 
 
 
Number of hospitalisation, 
duration of stay and costs 
Fewer hospital admissions (OR 0.76, 95% CI 0.66-
0.86), shorter length of stay and lower costs  in 
rasagiline group 
Grubb et al 2013[15] Retrospective 3864 
PD patients 
Rasagiline versus 
Selegiline 
 
Hospitalisation, emeregency 
room visits and falls 
Lower emergency room visits (odds ratio: 0.79; 95% 
CI, 0.68 to 0.92), lower all hospital admissions (odds 
ratio: 0.82; 95% CI, 0.68 to 0.99), and lower number of 
falls in rasagiline group 
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PD Mediation Adherence 
Delea et al 2011[16] Retrospective 
 
1215 
PD patients 
 
Adherence to 
levodopa/carbidopa/ 
entacopone  
 
All cause and PD- related 
hospitalisations, length of stay, 
emergency room and physicians 
visits, prescriptions and 
healthcare costs 
 
Satisfactory adherence versus non adherent: mean 
number PD related admissions (0.15 vs 0.12 ,p<0.001), 
emergency visits (0.04vs 0.08, p=0.010), all cause 
hospitalisation (0.30 vs 0.53, p<0.001) 
 
Kulkarni et al 2008[18] Retrospective 
Longitudinal 
cohort 
 
104 PD 
patients 
 
PD medication 
adherence 
 
Medication adherence, PD 
related hospitalisations and 
emergency room visits. 
 
Suboptimal adherence associated with worsening 
motor symptoms: Odds for adherers (MPR>0.8) 
experiencing symptom worsening compared to non-
adherers was 67% less (odd ratio 0.33 95% CI 0.13-
0.85) 
 
Wei et al 2014[17] 
 
 
 
Retrospective 
Crossectional 
study 
 
 
7583 PD 
patients 
 
 
 
 
PD medication 
adherence 
 
 
 
Hospital visits, emergency room 
visits , skilled nursing facility, 
home health agency, physcians 
visit and health costs 
 
Prevalence and relative risk (low versus high adherers): 
hospitalisation 57% vs 47% and 1 versus 0.86 (95% CI 
0.81-0.90),  
Emergency room visits 68% vs 59% and 1 versus 
0.91(95% CI 0.86-0.96) 
Davis et al 2010[19] Retrospective 3119 
PD patients 
PD medication 
adherence 
Medication adherence, health care 
utilisation (including hospital 
admissions and emergency 
room visits), and costs 
Mean hospitalisation per annum, non-compliant versus 
compliant: 2.3 versus 1.8; p<0.005. Mean number of 
emergency departments visits  were not significantly 
different 1.9 versus 1.8 
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Figure 1 : Flow diagram showing publications identified through database searching and 
reasons for inclusion and exclusion from the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications identified through 
database searching  
n = 7610 
Publications after duplicates removed  
n=7361 
Publications screened  
n=7361 
Publications excluded: n=7246 
Reasons for exclusion: 
No abstracts 
Non-English language 
Addressed hospitalisation 
in other conditions 
including Schizophrenia, 
dementia, stroke, 
Publications assessed for eligibility 
n=115 
Publications excluded n=105 
Reasons for exclusion:  
Hospitalisation in PD but 
no interventions assessed 
 
Publications included:   
Randomised controlled trials n=1 
Retrospective studies n=9 
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Highlights  
• Hospitalisation in Parkinson’s disease (PD) is a significant cost driver. 
• We reviewed the literature for interventions aimed at reducing hospitalisation in PD 
• There is a lack of robust evidence for interventions to reduce PD hospitalisation  
• Open access PD clinics, regular neurologist care and PD symptoms control may 
mitigate non-elective PD admissions. 
 
